Kathleen E Corey1,2, Uri Kartoun2,3, Hui Zheng2,4, Raymond T Chung1,2, Stanley Y Shaw2,3. 1. Liver Center, Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA. 2. Harvard Medical School, Boston, MA, USA. 3. Center for Systems Biology, Center for Assessment Technology and Continuous Health, Massachusetts General Hospital, Boston, MA, USA. 4. Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.
Abstract
OBJECTIVES: Among adults with nonalcoholic fatty liver disease (NAFLD), 25% of deaths are attributable to cardiovascular disease (CVD). CVD risk reduction in NAFLD requires not only modification of traditional CVD risk factors but identification of risk factors unique to NAFLD. METHODS: In a NAFLD cohort, we sought to identify non-traditional risk factors associated with CVD. NAFLD was determined by a previously described algorithm and a multivariable logistic regression model determined predictors of CVD. RESULTS: Of the 8,409 individuals with NAFLD, 3,243 had CVD and 5,166 did not. On multivariable analysis, CVD among NAFLD patients was associated with traditional CVD risk factors including family history of CVD (OR 4.25, P=0.0007), hypertension (OR 2.54, P=0.0017), renal failure (OR 1.59, P=0.04), and age (OR 1.05, P<0.0001). Several non-traditional CVD risk factors including albumin, sodium, and Model for End-Stage Liver Disease (MELD) score were associated with CVD. On multivariable analysis, an increased MELD score (OR 1.10, P<0.0001) was associated with an increased risk of CVD. Albumin (OR 0.52, P<0.0001) and sodium (OR 0.96, P=0.037) were inversely associated with CVD. In addition, CVD was more common among those with a NAFLD fibrosis score >0.676 than those with a score ≤0.676 (39 vs. 20%, P<0.0001). CONCLUSIONS: CVD in NAFLD is associated with traditional CVD risk factors, as well as higher MELD scores and lower albumin and sodium levels. Individuals with evidence of advanced fibrosis were more likely to have CVD. These findings suggest that the drivers of NAFLD may also promote CVD development and progression.
OBJECTIVES: Among adults with nonalcoholic fatty liver disease (NAFLD), 25% of deaths are attributable to cardiovascular disease (CVD). CVD risk reduction in NAFLD requires not only modification of traditional CVD risk factors but identification of risk factors unique to NAFLD. METHODS: In a NAFLD cohort, we sought to identify non-traditional risk factors associated with CVD. NAFLD was determined by a previously described algorithm and a multivariable logistic regression model determined predictors of CVD. RESULTS: Of the 8,409 individuals with NAFLD, 3,243 had CVD and 5,166 did not. On multivariable analysis, CVD among NAFLD patients was associated with traditional CVD risk factors including family history of CVD (OR 4.25, P=0.0007), hypertension (OR 2.54, P=0.0017), renal failure (OR 1.59, P=0.04), and age (OR 1.05, P<0.0001). Several non-traditional CVD risk factors including albumin, sodium, and Model for End-Stage Liver Disease (MELD) score were associated with CVD. On multivariable analysis, an increased MELD score (OR 1.10, P<0.0001) was associated with an increased risk of CVD. Albumin (OR 0.52, P<0.0001) and sodium (OR 0.96, P=0.037) were inversely associated with CVD. In addition, CVD was more common among those with a NAFLD fibrosis score >0.676 than those with a score ≤0.676 (39 vs. 20%, P<0.0001). CONCLUSIONS: CVD in NAFLD is associated with traditional CVD risk factors, as well as higher MELD scores and lower albumin and sodium levels. Individuals with evidence of advanced fibrosis were more likely to have CVD. These findings suggest that the drivers of NAFLD may also promote CVD development and progression.
Authors: Rita De Vito; Anna Alisi; Andrea Masotti; Sara Ceccarelli; Nadia Panera; Arianna Citti; Michele Salata; Luca Valenti; Ariel E Feldstein; Valerio Nobili Journal: Int J Mol Med Date: 2012-04-10 Impact factor: 4.101
Authors: Silvia Sookoian; Gustavo O Castaño; Adriana L Burgueño; María Soledad Rosselli; Tomas Fernández Gianotti; Pablo Mallardi; Julio San Martino; Carlos Jose Pirola Journal: Atherosclerosis Date: 2009-10-13 Impact factor: 5.162
Authors: Dana A Telem; Thomas Schiano; Robert Goldstone; Daniel K Han; Kerri E Buch; Edward H Chin; Scott Q Nguyen; Celia M Divino Journal: Clin Gastroenterol Hepatol Date: 2009-12-29 Impact factor: 11.382
Authors: Neeraj Bhala; Paul Angulo; David van der Poorten; Eric Lee; Jason M Hui; Giorgio Saracco; Leon A Adams; Phunchai Charatcharoenwitthaya; Joanne H Topping; Elisabetta Bugianesi; Christopher P Day; Jacob George Journal: Hepatology Date: 2011-08-09 Impact factor: 17.425
Authors: Tracey G Simon; Uri Kartoun; Hui Zheng; Andrew T Chan; Raymond T Chung; Stanley Shaw; Kathleen E Corey Journal: Hepatol Commun Date: 2017-05-22
Authors: Uri Kartoun; Rahul Aggarwal; Andrew L Beam; Jennifer K Pai; Arnaub K Chatterjee; Timothy P Fitzgerald; Isaac S Kohane; Stanley Y Shaw Journal: Sci Rep Date: 2018-05-18 Impact factor: 4.379